Advertisement
Research Article

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

  • Ann J. Hessell,

    Affiliation: Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America

    X
  • Eva G. Rakasz,

    Affiliation: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

    X
  • Pascal Poignard,

    Affiliations: Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America, International AIDS Vaccine Initiative (IAVI), New York, New York, United States of America

    X
  • Lars Hangartner,

    Affiliations: Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America, Institute of Medical Virology, University of Zürich, Zürich, Switzerland

    X
  • Gary Landucci,

    Affiliation: Division of Infectious Diseases, Department of Medicine, UC Irvine School of Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Donald N. Forthal,

    Affiliation: Division of Infectious Diseases, Department of Medicine, UC Irvine School of Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Wayne C. Koff,

    Affiliation: International AIDS Vaccine Initiative (IAVI), New York, New York, United States of America

    X
  • David I. Watkins,

    Affiliation: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

    X
  • Dennis R. Burton mail

    burton@scripps.edu

    Affiliation: Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America

    X
  • Published: May 15, 2009
  • DOI: 10.1371/journal.ppat.1000433

About the Authors

Ann J. Hessell, Pascal Poignard, Lars Hangartner, Dennis R. Burton
Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
Eva G. Rakasz, David I. Watkins
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
Pascal Poignard, Wayne C. Koff
International AIDS Vaccine Initiative (IAVI), New York, New York, United States of America
Lars Hangartner
Institute of Medical Virology, University of Zürich, Zürich, Switzerland
Gary Landucci, Donald N. Forthal
Division of Infectious Diseases, Department of Medicine, UC Irvine School of Medicine, University of California Irvine, Irvine, California, United States of America

Corresponding Author

Email: burton@scripps.edu

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: AJH EGR LH WCK DIW DRB. Performed the experiments: AJH EGR LH GL. Analyzed the data: AJH EGR PP LH GL DNF DRB. Contributed reagents/materials/analysis tools: DRB. Wrote the paper: AJH PP DRB. Managed the research project: AJH. Reviewed and edited the manuscript: LH DNF WCK DIW.